3-ethyl-5-phenylimidazolidine-2,4-dione

• ChemBase编号: 634
• 分子式: C11H12N2O2
• 平均质量: 204.22518
• 单一同位素质量: 204.08987763
• SMILES: O=C1N(C(=O)NC1c1ccccc1)CC
• Canonical SMILES: CCN1C(=O)NC(C1=O)c1ccccc1
• InChI: InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)
• InChIKey: SZQIFWWUIBRPBZ-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 3-ethyl-5-phenylimidazolidine-2,4-dione
• IUPAC传统名: 3-ethyl-5-phenylhydantoin; ethotoin
• 商标名: Accenon; Peganone; Pegoanone
• 别名: Ethotoine [INN-French]; Ethotoinum [INN-Latin]; Etotoina [INN-Spanish]; Ethotoin

登记号

• CAS号: 86-35-1
• PubChem SID: 160964097; 46504521
• PubChem CID: 3292
• CHEBI ID: 4888
• ATC码: N03AB01
• CHEMBL: 1095
• Chemspider ID: 3176
• DrugBank ID: DB00754
• KEGG ID: D00708
• 美国药典/FDA物质标识码: 46QG38NC4U
• 维基百科标题: Ethotoin
• Medline Plus: a682022

理论计算性质

JChem

• Acid pKa: 11.288526
• 质子受体: 2
• 质子供体: 1
• LogD (pH = 5.5): 1.0666922
• LogD (pH = 7.4): 1.0666375
• Log P: 1.066693
• 摩尔折射率: 55.0493 cm^3
• 极化性: 21.230879 Å^3
• 极化表面积: 49.41 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 1.11
• LOG S: -1.93
• 溶解度: 2.38e+00 g/l

分子性质

理化性质

• 溶解度: 5280 mg/L
• 疏水性(logP): 0.8

药理学性质

• 给药途径: Oral
• 半衰期: 3 to 9 hours
• 妊娠期药物分类: C

详细说明

DrugBank - DB00754

• Drug Groups: approved
• Description: Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges.
• Indication: For the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures.
• Pharmacology: Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges.
• Toxicity: Symptoms of overdose include drowsiness, loss of or impaired muscle coordination, nausea, visual disturbance, and, at very high doses, coma.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic. The drug exhibits saturable metabolism with respect to the formation of N-deethyl and p-hydroxyl-ethotoin, the major metabolites.
• Absorption: Fairly rapidly absorbed, however, the extent of oral absorption is not known.
• Half Life: 3 to 9 hours
• References: SCHWADE ED, RICHARDS RK, EVERETT GM: Peganone, a new antiepileptic drug. Dis Nerv Syst. 1956 May;17(5):155-8. [Pubmed]
• External Links: Wikipedia; RxList; PDRhealth; Drugs.com

参考文献

• SCHWADE ED, RICHARDS RK, EVERETT GM: Peganone, a new antiepileptic drug. Dis Nerv Syst. 1956 May;17(5):155-8. Pubmed